Alloplex Biotherapeutics Inc., a Boston-based cellular therapeutics company, announced the appointment of Mr. Paul Sowyrda to its Corporate Board this week.
Mr. Sowyrda brings over three decades of invaluable experience in the pharmaceutical and biotech industries to Alloplex. His extensive background includes co-founding and serving as Executive Vice President of Novellus, Inc., which was acquired by Brooklyn ImmunoTherapeutics, Inc. in 2021.
Throughout his career, Mr. Sowyrda has held key leadership positions at prominent pharmaceutical companies. He served as Vice President of Drug Development at CIBA, Vice President of Development and Marketing at Dusa Pharmaceuticals (acquired by Sun Pharma in 2012), and Vice President of Product Development for Chiron Corporation.
A prolific inventor, Mr. Sowyrda holds over 15 patents in various fields. His expertise extends beyond the corporate realm, as evidenced by his service on the Board of Directors for The Society of Concurrent Product Development and his membership in both the American Academy of Dermatology and the International Society of Dermatologic Surgery.
Mr. Sowyrda’s educational background is equally impressive. He earned his B.S. from Northeastern University, M.S. from the University of Notre Dame, and MBA from Babson College. Additionally, he completed the MIT Sloan School of Management Senior Executives Program.
Dr. Frank Borriello, CEO of Alloplex, expressed his enthusiasm for the appointment, which received overwhelming support from investors holding over 95% of voting shares, “Paul brings a comprehensive strategic perspective on the field of cellular therapy and will make an excellent addition to our Corporate Board.”
Coinciding with Mr. Sowyrda’s appointment, effective August 19, 2024, Alloplex announces the departure of Mr. Jared Chung from the Board after three years of service. Dr. Borriello extended his personal gratitude to Mr. Chung on this occasion for his stewardship and attention to detail during his tenure.
Alloplex Biotherapeutics, founded in 2016, is a privately-held company at the forefront of developing innovative cellular therapies for cancer treatment. The company’s proprietary ENLIST cell platform generates SUPLEXA therapeutic cells, which have shown a reassuring safety profile and early signs of clinical efficacy in early single-agent clinical studies amongst late-stage patients with solid cancer tumors.
To request interviews, high res images or other materials, media are asked to:
Email: media@alloplexbio.com
Attn: Lesley White, Alloplex Australia
For media requests on deadline during USA Eastern hours, please call: +1-781-281-2013
